Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Montelukast. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN110903188A reveals a novel one-pot synthesis for tribromoneopentanol acetate using in-situ HBr generation, offering high purity and scalable manufacturing for pharmaceutical intermediates.
Patent CN115819300B enables high yield synthesis. Reduces toxic reagents. Reliable supply chain partner for pharmaceutical intermediates.
Discover the patented cyanide-free route for 1-mercaptomethylcyclopropyl acetic acid. Enhance supply chain safety and reduce manufacturing costs with scalable technology.
Patent CN112724082B details a cost-effective copper-catalyzed route for montelukast intermediates, offering superior purity and supply chain stability for global pharmaceutical manufacturers.
Patent CN107778228A reveals advanced recrystallization for Montelukast Sodium ensuring high purity and yield. Discover supply chain advantages and cost reduction in pharmaceutical intermediates manufacturing with our expert analysis.
Patent CN103524408A details a high-yield aqueous synthesis of 7-chloroquinaldine using SDS and phosphomolybdic acid, offering significant cost and purity advantages for pharmaceutical manufacturing.
Patent CN112094212A reveals a robust method for 1-(mercaptomethyl)cyclopropylacetic acid, offering superior yield and purity for pharmaceutical supply chains.
Patent CN101356158A details a robust Montelukast synthesis using stable thiolactone intermediates and activated cerium catalysis for superior purity and supply chain reliability.
Discover a streamlined method for producing high-purity Montelukast sodium intermediates. This patent analysis reveals cost-effective manufacturing strategies for API suppliers.
Patent CN101501000B details a novel purification process for Montelukast using chiral amine salts, offering high optical purity and cost reduction in pharmaceutical intermediate manufacturing without chromatography.
Patent CN103554016B reveals enzymatic synthesis for high-purity API intermediates. Achieve substantial cost reduction and supply chain reliability with scalable green chemistry solutions.
Patent CN118421578A reveals high-efficiency carbonyl reductase for Montelukast intermediate. Offers cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN106928136B details graphene palladium cobalt catalysis for montelukast intermediate. Offers high yield and chiral selectivity for reliable pharmaceutical intermediate supply chains.
Patent CN106928136A reveals graphene palladium cobalt catalyst for Montelukast intermediate. Enhances purity and supply chain reliability for pharmaceutical manufacturing.
Patent CN103073492A details a green Ru-catalyzed transfer hydrogenation for Montelukast intermediates, offering significant cost reduction and supply chain reliability.
Novel aqueous-based method for Montelukast improves yield and safety. Ideal for reliable pharmaceutical intermediate supplier partnerships.
Advanced synthesis of Montelukast Sodium via CN111892535B. Achieves >99.8% purity and >93.5% yield without expensive ionic liquids, offering significant cost reduction.
Patent CN104592110A reveals cost-effective chiral reduction for Montelukast intermediate ensuring high purity and scalable supply chain reliability for global pharmaceutical manufacturers
Novel nucleophilic substitution route for Montelukast intermediate. High optical purity, mild conditions, cost-effective manufacturing for global supply chains.
Novel synthesis route for Montelukast Sodium intermediates via CN102424673B. Offers cost reduction in API manufacturing and enhanced supply chain reliability for global buyers.